Mirum Pharmaceuticals, INC

Mirum Pharmaceuticals, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Mirum Pharmaceuticals announced the pricing of its $600 million offering of 0.00% Convertible Senior Notes due 2032, with net proceeds expected to be approximately $583.8 million.

Mirum Pharmaceuticals reported robust Q1 2026 results with increased net product sales and raised full-year guidance, alongside significant pipeline progress including a new drug application acceptance for zilurgisertib.

Mirum Pharmaceuticals announced its investigational drug volixibat met the primary endpoint in a Phase 2b study for primary sclerosing cholangitis (PSC), showing significant improvement in pruritus.

Mirum Pharmaceuticals announced positive primary endpoint results from the Phase 2b AZURE-1 study of brelovitug for chronic hepatitis delta virus.

Mirum Pharmaceuticals has amended its Form 8-K to include financial statements and pro forma information following its acquisition of Bluejay Therapeutics and a concurrent private placement.

Mirum Pharmaceuticals announces a significant increase in product sales and substantial R&D investment in its Q1 2026 results.

Mirum Pharmaceuticals, Inc. reported a net income of $2.9 million for the third quarter of 2025, driven by significant increases in product sales, particularly Livmarli and Bile Acid Medicines.

Mirum Pharmaceuticals reports significant revenue growth and a substantial reduction in net loss for Q2 2025, driven by strong product sales and pipeline advancements.

Mirum Pharmaceuticals' Q1 2025 revenue increased significantly, driven by strong sales of Livmarli and Bile Acid Medicines, while the company continues to invest in its pipeline and commercial infrastructure.

Mirum Pharmaceuticals saw a significant increase in product sales in the third quarter of 2024, driven by both Livmarli and Bile Acid Medicines, though the company continues to operate at a net loss.

Mirum Pharmaceuticals saw a significant increase in revenue in the second quarter of 2024, primarily driven by sales of Livmarli and the newly acquired Bile Acid Medicines.

Mirum Pharmaceuticals, Inc. reported significant revenue growth in 2025, driven by its approved rare disease medicines, while actively expanding its clinical pipeline and navigating ongoing patent litigation.

Mirum Pharmaceuticals' 2024 10-K filing highlights increased product sales, ongoing clinical trials, and strategic portfolio expansion in rare disease treatments.

Mirum Pharmaceuticals' 10-K filing details its common stock terms, business strategy, product pipeline, and financial agreements, highlighting its focus on rare and orphan diseases.

Mirum Pharmaceuticals CEO Christopher Peetz reported transactions involving company stock, including the acquisition of shares and the sale of a significant number of shares under a Rule 10b5-1 trading plan.

Mirum Pharmaceuticals' Chief Financial Officer, Eric Bjerkholt, has sold a total of 4,722 shares of common stock under a pre-arranged trading plan.

Jolanda Howe, SVP Global Controller at Mirum Pharmaceuticals, reported a sale of 2,721 common stock shares on July 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe, SVP Global Controller at Mirum Pharmaceuticals, reported a sale of 2,594 shares of common stock on June 17, 2026, executed under a Rule 10b5-1 trading plan.

Director Timothy P. Walbert received an equity grant of stock options and restricted stock units from Mirum Pharmaceuticals.

Director Lon Cardon received an equity grant of stock options and restricted stock units from Mirum Pharmaceuticals.

Mirum Pharmaceuticals has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation.

Mirum Pharmaceuticals has filed definitive additional materials related to its proxy statement with the SEC.

Mirum Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders on May 29, 2025, to elect directors, ratify the selection of Ernst & Young LLP as the independent registered public accounting firm, and conduct an advisory vote on executive compensation.

Mirum Pharmaceuticals has filed definitive additional materials related to its proxy statement with the SEC.

Mirum Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, in a hybrid format.

Frazier Life Sciences funds and affiliates updated their beneficial ownership in Mirum Pharmaceuticals, detailing recent share acquisitions and a merger-related stock issuance.

Frazier Life Sciences Public Fund increased its beneficial ownership in Mirum Pharmaceuticals, Inc. following a merger with Frazier Life Sciences Public Overage Fund.

Frazier Life Sciences entities and associated individuals have filed an Amendment No. 6 to their Schedule 13D for Mirum Pharmaceuticals, Inc., clarifying beneficial ownership attribution for certain funds.

BlackRock Inc. has disclosed a beneficial ownership of 5.7% in Mirum Pharmaceuticals, Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Mirum Pharmaceuticals Inc. following an internal realignment.

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, reported a 4.1% beneficial ownership stake in Mirum Pharmaceuticals, Inc. as of December 31, 2025.

Janus Henderson Group plc has disclosed an increased beneficial ownership of 10.6% in Mirum Pharmaceuticals, Inc. common stock.

Biotechnology Value Fund and its affiliates reported a collective 3.0% passive ownership stake in Mirum Pharmaceuticals, Inc. as of September 30, 2025.

Janus Henderson Group plc has increased its beneficial ownership in Mirum Pharmaceuticals, Inc. to 10.0% of common stock.